Generative AI
Veranova, Phorum.AI Partner On Generative AI Chemistry Optimization
Veranova and Phorum.AI are collaborating on next-generation optimization of pharmaceutical manufacturing processes using artificial intelligence (AI).
Leveraging research and experimentation by Phorum.AI co-founder and MIT Professor of Chemistry, Brad Pentelute, Phorum.AI is deploying generative AI systems to help biopharmaceutical companies rapidly develop optimized manufacturing processes that aim to reduce costs, speed development timelines, and reduce environmental footprint.
The companies will leverage Veranova’s empirical manufacturing dataset, developed over 20 years of manufacturing a portfolio of owned active pharmaceutical ingredient (API) drug master files (DMFs), and Phorum.AI’s generative AI to develop a tool that aims to enable development of optimized manufacturing processes in a fraction of the time versus historical methods.
“Phorum.AI and Veranova have the potential to create a step change in the quality and development efficiency of pharmaceutical processing”, said Mike Riley, CEO of Veranova. “We are delighted to partner with a leading AI technology innovator to be able to offer our clients a new capability that has the potential to develop optimized manufacturing processes at an accelerated pace.”
“By partnering with Veranova, a worldwide leader in developing and manufacturing APIs, we are able to more rapidly scale our market footprint and create greater impact sooner”, Dan Chinnapen, CEO of Phorum.AI, adding “We are excited to reduce time to market and mitigate costs for much-needed therapeutics.”
The two companies are collaborating on a commercial partnership that enables Veranova clients to benefit from an integrated scale-up solution powered by Phorum.AI’s technology.
Leveraging research and experimentation by Phorum.AI co-founder and MIT Professor of Chemistry, Brad Pentelute, Phorum.AI is deploying generative AI systems to help biopharmaceutical companies rapidly develop optimized manufacturing processes that aim to reduce costs, speed development timelines, and reduce environmental footprint.
The companies will leverage Veranova’s empirical manufacturing dataset, developed over 20 years of manufacturing a portfolio of owned active pharmaceutical ingredient (API) drug master files (DMFs), and Phorum.AI’s generative AI to develop a tool that aims to enable development of optimized manufacturing processes in a fraction of the time versus historical methods.
“Phorum.AI and Veranova have the potential to create a step change in the quality and development efficiency of pharmaceutical processing”, said Mike Riley, CEO of Veranova. “We are delighted to partner with a leading AI technology innovator to be able to offer our clients a new capability that has the potential to develop optimized manufacturing processes at an accelerated pace.”
“By partnering with Veranova, a worldwide leader in developing and manufacturing APIs, we are able to more rapidly scale our market footprint and create greater impact sooner”, Dan Chinnapen, CEO of Phorum.AI, adding “We are excited to reduce time to market and mitigate costs for much-needed therapeutics.”
The two companies are collaborating on a commercial partnership that enables Veranova clients to benefit from an integrated scale-up solution powered by Phorum.AI’s technology.
